TY - JOUR A2 - Mussano，费德里科AU - Durgam，Sushmitha S. AU - 阿尔特曼，纳丁N. AU - 考夫林，海利E. AU - 罗林，奥黛丽AU - Hostnik，劳拉D. PY - 2019 DA - 2019/12 /27 TI - 胰岛素增强屈肌腱来源的祖细胞SP的体外成骨容量 - 1602751 VL - 2019 AB - 有增加腱病症的发病率和在人糖尿病患者（DM）减小肌腱愈合的能力。最近的研究还表明在人与DM修复肌腱骨化病变。因此，本研究的目的是调查胰岛素补充，DM的一个重要的病理生理的刺激，对腱祖细胞（TPC）的增殖和体外成骨能力的影响。通道3级的TPC从胶原酶消化，马数字浅屈肌腱隔离。TPC proliferation was measured via MTT assay after 3 days of monolayer culture in medium supplemented with 0, 0.007, 0.07, and 0.7 nM insulin. In vitro osteogenic capacity of TPCs (Alizarin Red staining, osteogenic mRNA expression, and alkaline phosphatase bioactivity) was assessed with 0, 0.07, and 0.7 nM insulin-supplemented osteogenic induction medium. Insulin (0.7 nM) significantly increased TPC proliferation after 3 days of monolayer culture. Alizarin Red staining of insulin-treated TPC osteogenic cultures demonstrated robust cell aggregation and mineralized matrix secretion, in a dose-dependent manner. Runx2, alkaline phosphatase, and Osteonectin mRNA and alkaline phosphatase bioactivity of insulin-treated TPC cultures were significantly higher at day 14 of osteogenesis compared to untreated controls. Addition of picropodophyllin (PPP), a selective IGF-I receptor inhibitor, mitigated the increased osteogenic capacity of TPCs, indicating that IGF-I signaling plays an important role. Our findings indicate that hyperinsulinemia may alter TPC phenotype and subsequently impact the quality of repair tendon tissue. SN - 1687-966X UR - https://doi.org/10.1155/2019/1602751 DO - 10.1155/2019/1602751 JF - Stem Cells International PB - Hindawi KW - ER -